Artwork

Innhold levert av PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

Rohit Loomba, MD, MHSc - Hope Is on the Horizon for Nonalcoholic Steatohepatitis: Leveraging the Power of Next Generation Monitoring and Pharmacotherapies

25:47
 
Del
 

Manage episode 372728804 series 82214
Innhold levert av PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Go online to PeerView.com/RVV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hepatology discusses NAFLD and NASH as metabolic diseases and potential therapeutic targets for patients with the conditions. Upon completion of this activity, participants should be better able to: Describe the disease pathways and mechanisms that define NAFLD/NASH as metabolic diseases; Discuss the pathophysiology and role of GLP-1 as a therapeutic target in NAFLD/NASH and other metabolic conditions; Use noninvasive tests and biomarkers to monitor NAFLD/NASH disease progression; and Initiate early guideline-driven and pathway-driven management with available and emerging pharmacotherapies to delay NAFLD/NASH progression and improve outcomes for patients
  continue reading

55 episoder

Artwork
iconDel
 
Manage episode 372728804 series 82214
Innhold levert av PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Go online to PeerView.com/RVV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hepatology discusses NAFLD and NASH as metabolic diseases and potential therapeutic targets for patients with the conditions. Upon completion of this activity, participants should be better able to: Describe the disease pathways and mechanisms that define NAFLD/NASH as metabolic diseases; Discuss the pathophysiology and role of GLP-1 as a therapeutic target in NAFLD/NASH and other metabolic conditions; Use noninvasive tests and biomarkers to monitor NAFLD/NASH disease progression; and Initiate early guideline-driven and pathway-driven management with available and emerging pharmacotherapies to delay NAFLD/NASH progression and improve outcomes for patients
  continue reading

55 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett